Compare Corning Incorporated (GLW) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Eli Lilly And Co — how do they compare? Corning Incorporated trades at $157.3 (market cap $131.65B), while Eli Lilly And Co trades at $1,169 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 7.9× Corning Incorporated's market cap, and Corning Incorporated pays the higher dividend (0.73%). Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 35 Days and Eli Lilly And Co for 93 Days on average.
| GLW | LLY | |
|---|---|---|
Market Cap | $131.65B | $1.04T |
Volume | 8,992,522 | 3,064,878 |
Sector | Technology | Health |
52-Week High | $255.79 | $1.28K |
52-Week Low | $78.03 | $799.57 |
Typical Hold Time | 35 Days | 93 Days |
Enterprise Value | $138.52B | $1.09T |
Dividend Yield | 0.73% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $163.21, down 3.41% today, but maintains a bullish technical outlook with strong support at $160. The company recently secured a significant $3 billion fiber supply agreement with AT&T, boosting growth prospects in the AI infrastructure sector. Despite elevated valuation ratios (P/E 75.23), GLW has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $0.878. Operating cash flow improved to $2.7 billion in 2025, supporting the company's dividend payments and strategic investments.
GLW presents a compelling growth story driven by AI infrastructure demand, with analyst consensus favoring Buy ratings (56.75%) and a $171.25 price target offering 5% upside. Key risks include patent litigation concerns and the stock's premium valuation requiring sustained earnings growth. The AT&T partnership positions Corning to capitalize on expanding fiber optic needs, though investors should monitor competitive pressures and execution risks in the rapidly evolving technology sector.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
